These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 29574562)

  • 1. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
    Mustafa SS; Ostrov D; Yerly D
    Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
    Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
    Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug reaction with eosinophilia and systemic symptoms].
    Tehrany YA; Laffitte E; Grosgurin O; Spoerl D
    Rev Med Suisse; 2016 Apr; 12(513):684-6, 688-90. PubMed ID: 27197323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
    Owen CE; Jones JM
    Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse cutaneous drug eruptions: current understanding.
    Hoetzenecker W; Nägeli M; Mehra ET; Jensen AN; Saulite I; Schmid-Grendelmeier P; Guenova E; Cozzio A; French LE
    Semin Immunopathol; 2016 Jan; 38(1):75-86. PubMed ID: 26553194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
    Godfrey H; Jedlowski P; Thiede R
    Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Perspectives on Severe Drug Eruption.
    Zhang J; Lei Z; Xu C; Zhao J; Kang X
    Clin Rev Allergy Immunol; 2021 Dec; 61(3):282-298. PubMed ID: 34273058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking.
    Walsh SA; Creamer D
    Clin Exp Dermatol; 2011 Jan; 36(1):6-11. PubMed ID: 21143513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
    Loo CH; Tan WC; Khor YH; Chan LC
    Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatments for Severe Cutaneous Adverse Reactions.
    Cho YT; Chu CY
    J Immunol Res; 2017; 2017():1503709. PubMed ID: 29445753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.
    Paulmann M; Mockenhaupt M
    Curr Pharm Des; 2016; 22(45):6852-6861. PubMed ID: 27779083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
    Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
    Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe cutaneous adverse reactions: A 5-year retrospective study at Hospital Melaka, Malaysia, from December 2014 to February 2020.
    Tee CT; Abdullah NH; Kristummoonthy P; Lee CS
    Med J Malaysia; 2022 Jul; 77(4):409-414. PubMed ID: 35902928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
    Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
    Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient management and follow-up recommendations for adverse drug reactions: guidelines for posthospitalization care.
    Khanna R; Vaudreuil A; Lake E
    Cutis; 2019 May; 103(5):254-256;258. PubMed ID: 31233575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
    Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
    Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Saudi Arabia.
    AlJasser MI
    Dermatol Res Pract; 2023; 2023():8928198. PubMed ID: 37206671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).
    Torres-Navarro I; de Unamuno-Bustos B; Botella-Estrada R
    J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):607-614. PubMed ID: 32846030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe cutaneous adverse reactions related to systemic antibiotics.
    Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH
    Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan.
    Huang YS; Wu CY; Chang TT; Peng CY; Lo GH; Hsu CW; Hu CT; Huang YH
    Liver Int; 2021 Nov; 41(11):2671-2680. PubMed ID: 34153177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.